Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACD856
Therapeutic Area: Neurology Product Name: ACD856
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
The Phase I study is AlzeCure's second clinical study with ACD856, the company's leading drug candidate in the NeuroRestore platform, and is being developed as a symptom-relieving treatment for conditions where cognitive impairment is impaired, such as Alzheimer's disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACD856
Therapeutic Area: Neurology Product Name: ACD856
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
Details:
The abstract demonstrates that AlzeCure's leading drug candidate in the company's NeuroRestore platform, ACD856, has the potential for wide use in various types of cognitive memory disorders.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ACD856
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2020
Details:
Data show that ACD856, has a good pharmacokinetic profile with a significantly shorter human half-life than its predecessor ACD855 and that the candidate is suitable for further clinical development such as oral treatment of Alzheimer's disease, among others.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ketorolac
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
Details:
OX338 demonstrated improved bioavailability and tolerability compared to commercially available reference product.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
